Splice variants of the cyclic nucleotide phosphodiesterase PDE4D are differentially expressed and regulated in rat tissue.
Cyclic nucleotide PDE4 (phosphodiesterase 4) inhibitors are being developed as potent anti-inflammatory drugs for use in chronic lung diseases, but the complexity of the PDE4 family has hampered this process. The four genes comprising the PDE4 family, PDE4A, PDE4B, PDE4C and PDE4D, are all expressed as multiple splice variants. The most widely used criterion to identify PDE4 variants expressed endogenously is their migration on SDS/PAGE. However, when a PDE4D3-selective antibody was used for immunoprecipitation, the pattern of expression obtained did not confirm the expression predicted by SDS/PAGE. This observation, together with the recent discovery of additional PDE4D transcripts, prompted us to re-evaluate the pattern of expression of these variants. The nine rat PDE4D splice variants, PDE4D1 to PDE4D9, were cloned, their electrophoretic properties compared, and their in vivo mRNA and protein levels determined. Using this approach, we found that the pattern of distribution of the PDE4D splicing variants is more complex than previously reported. Multiple variants co-migrate in single immunoreactive bands, and variant-selective antibodies were necessary to discriminate between splice variants. Tissues that were thought to express only PDE4D3, express three closely related proteins, with PDE4D8 and PDE4D9 as the predominantly expressed forms. In addition, activation of cAMP signalling produces phosphorylation and activation of variants other than PDE4D3, and expression of PDE4D mRNA does not always correlate with the pattern of protein expression. As PDE4 inhibitors have different affinities for distinct PDE4D splicing variants, our results indicate that a better definition of the pattern of PDE4 expression is required for target validation.
Richter
Wito
W
Division of Reproductive Biology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305-5317, USA.
Jin
S-L Catherine
SL
Conti
Marco
M
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D017398:Alternative Splicing / Q000235:genetics*; D000818:Animals; D001921:Brain / Q000378:metabolism; D002460:Cell Line; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; D020869:Gene Expression Profiling; D015971:Gene Expression Regulation, Enzymologic; D006801:Humans; D007668:Kidney / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D008297:Male; D009206:Myocardium / Q000378:metabolism; D017434:Protein Structure, Tertiary; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D051381:Rats; D013737:Testis / Q000378:metabolism; D013961:Thyroid Gland / Q000166:cytology / Q000378:metabolism
D012333:RNA, Messenger; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; D054703:Cyclic Nucleotide Phosphodiesterases, Type 4; C517355:PDE4A protein, human; C517360:PDE4B protein, human; C517361:PDE4C protein, human; C517376:PDE4D protein, human
J Biol Chem. 2000 Apr 14;275(15):10831-7
10753877
Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):11998-2003
10518565
Prog Nucleic Acid Res Mol Biol. 2001;66:241-77
11051766
J Biol Chem. 2000 Oct 27;275(43):33379-87
10938092
Annu Rev Pharmacol Toxicol. 2001;41:751-73
11264475
Biochim Biophys Acta. 2001 Jul 25;1540(1):68-81
11476896
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13049-54
11606735
FEBS Lett. 2002 Feb 13;512(1-3):205-8
11852080
Curr Opin Cell Biol. 2002 Apr;14(2):160-6
11891114
Br J Pharmacol. 2002 Jun;136(3):421-33
12023945
Proc Natl Acad Sci U S A. 2002 May 28;99(11):7628-33
12032334
J Clin Invest. 2002 Oct;110(7):1045-52
12370283
J Biol Chem. 2002 Oct 25;277(43):40212-21
12177055
Urology. 2002 Sep;60(2 Suppl 2):4-11
12414329
Biochem J. 2003 Feb 15;370(Pt 1):1-18
12444918
J Biol Chem. 2003 Feb 21;278(8):5493-6
12493749
Cell Signal. 2003 Sep;15(9):883-91
12834813
J Biol Chem. 2003 Aug 29;278(35):33351-63
12810716
Nat Genet. 2003 Oct;35(2):131-8
14517540
Drugs. 2003;63(23):2575-94
14636078
Biochem Soc Trans. 2003 Dec;31(Pt 6):1186-90
14641023
J Biol Chem. 2003 Dec 5;278(49):49230-8
14500724
Trends Pharmacol Sci. 2004 Mar;25(3):158-63
15019272
J Biol Chem. 2004 Jul 16;279(29):30338-48
15131123
Nature. 1970 Aug 15;227(5259):680-5
5432063
Biochemistry. 1971 Jan 19;10(2):311-6
4321663
Proc Natl Acad Sci U S A. 1989 Jul;86(14):5325-9
2546153
Proc Natl Acad Sci U S A. 1989 Nov;86(21):8197-201
2554303
J Mol Biol. 1991 Dec 5;222(3):553-65
1660926
Mol Cell Biol. 1993 Oct;13(10):6558-71
8413254
J Biol Chem. 1994 Jul 15;269(28):18271-4
8034568
Endocr Rev. 1995 Jun;16(3):370-89
7671852
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):295-9
8552625
J Biol Chem. 1996 Jul 12;271(28):16526-34
8663227
Mol Pharmacol. 1998 Jan;53(1):23-32
9443929
J Biol Chem. 1998 Jul 31;273(31):19672-8
9677395
EMBO J. 1999 Feb 15;18(4):893-903
10022832
Prog Nucleic Acid Res Mol Biol. 1999;63:1-38
10506827
J Biol Chem. 2000 Aug 25;275(34):26615-24
10851231